SEC Form SC 13G filed by Charles River Laboratories International Inc.

2/9/22 9:11:44 AM ET

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Get the next $CRL alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No. 0 CHARLES RIVER LABS INTL INC COMMON STOCK Cusip #159864107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #159864107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 199,406 Item 6: 0 Item 7: 2,770,128 Item 8: 0 Item 9: 2,770,128 Item 11: 5.489% Item 12: HC Cusip #159864107 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 2,770,128 Item 8: 0 Item 9: 2,770,128 Item 11: 5.489% Item 12: IN Item 1(a). Name of Issuer: CHARLES RIVER LABS INTL INC Item 1(b). Address of Issuer's Principal Executive Offices: 251 Ballardvale Street Wilmington, MA 01887 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 159864107 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 2,770,128 (b) Percent of Class: 5.489% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 199,406 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 2,770,128 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of CHARLES RIVER LABS INTL INC. No one other person's interest in the COMMON STOCK of CHARLES RIVER LABS INTL INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2022 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company LLC ("FMR Co. LLC"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2022, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of CHARLES RIVER LABS INTL INC at December 31, 2021. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.

Get the next $CRL alert in real time by email

Recent Analyst Ratings for

$CRL

Date	Price Target	Rating	Analyst
5/14/2025	$179.00	Hold → Buy	TD Cowen
5/8/2025	$170.00	In-line → Outperform	Evercore ISI
3/21/2025	$190.00 → $170.00	Buy → Neutral	Goldman
3/4/2025	$155.00 → $175.00	Sell → Neutral	Citigroup
3/3/2025	$188.00	Sell → Neutral	Redburn Atlantic
1/22/2025		Outperform → Mkt Perform	William Blair
1/17/2025	$250.00 → $185.00	Buy → Neutral	UBS
11/18/2024	$164.00	Hold → Underperform	CLSA

More analyst ratings

SEC Form SC 13G filed by Charles River Laboratories International Inc.

Chat with this insight

Recent Analyst Ratings for $CRL

$CRL SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Charles River Laboratories International Inc.

SEC Form 10-Q filed by Charles River Laboratories International Inc.

Charles River Laboratories International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

$CRL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Charles River upgraded by TD Cowen with a new price target

Charles River upgraded by Evercore ISI with a new price target

Charles River downgraded by Goldman with a new price target

$CRL Leadership Updates

Live Leadership Updates

Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery

Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors

$CRL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Corporate Executive VP & CFO Pease Flavia covered exercise/tax liability with 889 shares, decreasing direct ownership by 8% to 10,661 units (SEC Form 4)

Corporate Executive VP & COO Girshick Birgit gifted 430 shares, decreasing direct ownership by 0.78% to 54,628 units (SEC Form 4)

Chairman, President and CEO Foster James C bought $1,002,436 worth of shares (6,075 units at $165.01), increasing direct ownership by 3% to 183,639 units (SEC Form 4)

$CRL Financials

Live finance-specific insights

Charles River Laboratories Announces First-Quarter 2025 Results

Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance

$CRL Press Releases

Fastest customizable press release news feed in the world

Charles River Laboratories to Present at Bank of America Health Care Conference

Charles River Laboratories Announces First-Quarter 2025 Results

Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

$CRL Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Charles River Laboratories International Inc.

Amendment: SEC Form SC 13G/A filed by Charles River Laboratories International Inc.

SEC Form SC 13G/A filed by Charles River Laboratories International Inc. (Amendment)

$CRL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chairman, President and CEO Foster James C bought $1,002,436 worth of shares (6,075 units at $165.01), increasing direct ownership by 3% to 183,639 units (SEC Form 4)

Corporate Executive VP & COO Girshick Birgit bought $249,250 worth of shares (1,514 units at $164.63), increasing direct ownership by 3% to 55,058 units (SEC Form 4)

Girshick Birgit gifted 350 shares and bought $248,298 worth of shares (1,322 units at $187.82), increasing direct ownership by 53% to 44,449 units (SEC Form 4)

Recent Analyst Ratings for
$CRL

$CRL
SEC Filings

$CRL
Analyst Ratings

$CRL
Leadership Updates

$CRL
Insider Trading

$CRL
Financials

$CRL
Press Releases

$CRL
Large Ownership Changes

$CRL
Insider Purchases